Kadimastem

Ness Ziona, Israel Founded: 2009 • Age: 17 yrs
Stem cell therapies for diabetes and ALS are developed.
Request Access

About Kadimastem

Kadimastem is a company based in Ness Ziona (Israel) founded in 2009.. The company has 11 employees as of December 31, 2024. Kadimastem operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.

  • Headquarter Ness Ziona, Israel
  • Employees 11 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Kadimastem Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $0 (USD)
    0
    as on Dec 31, 2024
  • Net Profit
    $-7.28 M (USD)
    -121.1
    as on Dec 31, 2024
  • EBITDA
    $-1.39 M (USD)
    42
    as on Dec 31, 2024
  • Latest Funding Round
    $5.01 M (USD), Post-IPO

    Oct 25, 2021

  • Investors
  • Employee Count
    11

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Kadimastem

Kadimastem is a publicly listed company on the TASE with ticker symbol KDST in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TASE · Ticker: KDST . Sector: Health technology · Israel
People of Kadimastem
Headcount 10-50
Employee Profiles 10
Board Members and Advisors 11
Employee Profiles
People
Asaf Shiloni
Chief Executive Officer
People
Hanna Oppenheimer
Research Assistant
People
Doron Birger
Director
People
Michal Werbner
Reaserch Assistant

Unlock access to complete

Funding Insights of Kadimastem

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $5.0M
  • First Round

    (01 Jan 2016)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2021 Amount Post-IPO - Kadimastem Valuation

investors

Oct, 2018 Amount Post-IPO - Kadimastem Valuation

investors

Mar, 2018 Amount Grant - Kadimastem Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Kadimastem

Kadimastem has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, Altshuler Shaham and Clover Wolf Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
-
Founded Year Domain Location
Diversified investment management services are provided to various clients.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Kadimastem

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Kadimastem

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Kadimastem Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Kadimastem

Kadimastem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Developer of small molecule therapeutics for endocrine and CNS disorders
domain founded_year HQ Location
Small molecule drugs for rare diseases are developed.
domain founded_year HQ Location
Therapies for neurological and neuropsychiatric diseases are developed.
domain founded_year HQ Location
Genetically engineered cell therapies are developed for multiple disorders.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Kadimastem

When was Kadimastem founded?

Kadimastem was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is Kadimastem located?

Kadimastem is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.

How many employees does Kadimastem have?

As of Dec 31, 2024, the latest employee count at Kadimastem is 11.

What does Kadimastem do?

Founded in 2009 and based in Ness Ziona, Israel, regenerative medicine efforts are directed toward developing and commercializing stem cell-based therapeutics for diabetes mellitus and amyotrophic lateral sclerosis. Proprietary technologies are used to differentiate stem cells into insulin-secreting beta cells and neural cells such as astrocytes and oligodendrocytes. Therapeutic programs are advanced for implantation to address disease progression, with collaborations focused on drug development using pluripotent stem cell-derived cells.

Who are the top competitors of Kadimastem?

Kadimastem's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.

Is Kadimastem publicly traded?

Yes, Kadimastem is publicly traded on TASE under the ticker symbol KDST.

Who are Kadimastem's investors?

Kadimastem has 9 investors. Key investors include European Union, Altshuler Shaham, Clover Wolf Capital, Alpha Capital Anstalt, and Yehuda Feinberg.

What is Kadimastem's ticker symbol?

The ticker symbol of Kadimastem is KDST on TASE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available